deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01849250

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease

Sponsor: National Cancer Institute (NCI)

Conditions Benign Breast Neoplasm Ductal Breast Carcinoma In Situ Invasive Breast Carcinoma Lobular Breast Carcinoma In Situ Paget Disease of the Breast Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer
Interventions Docosahexaenoic Acid Placebo
Updated 8 times since 2017 Last updated: Dec 3, 2021 Started: May 31, 2013 Primary completion: Jan 11, 2016 Completion: Apr 22, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01849250, this PHASE2 trial focuses on Benign Breast Neoplasm and Ductal Breast Carcinoma In Situ and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshotActive Not Recruiting~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshotUnknown Status~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

  4. Jan 2021 — Jan 2022 [monthly]

    Unknown Status PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

▶ Show 3 earlier versions

  1. Apr 2018 — Jun 2018 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  2. Feb 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations